How can anyone have implicit faith in the science and products produced by BIG Pharma when The Wall Street Journal on October 5, 2010 featured the article “Drug Firms Face Bribery Probe” by Michael Rothfeld?
That question automatically should be followed with, “Will those charges also implicate the U.S. FDA?” Not knowing all the facts, but being of a suspicious nature, I’d say anything is possible given the long-term revolving door policy that seems to exist within government agencies, Big Pharma, and the chemical industry. This is where the U.S. Congress, in my opinion, has been—and continues to be—remiss in its oversight duties.
If one studies pharmaceutical demographics, as I have for years, one readily realizes that starting in the 1980s, Big Pharma companies began their push and drive to manage healthcare via their products by using what many feel are scare tactics in media advertising and unreliable science—something that the FDA apparently condones and even seems to parrot.
Read all HERE
No comments:
Post a Comment